拉考沙胺片联合左乙拉西坦片治疗难治性局灶性癫痫的效果

doi:10.3969/j.issn.1671-7171.2026.08.006

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1161 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the efficacy of lacosamide tablets combined with levetiracetam tablets in the treatment of drug-resistant focal epilepsy (DRE) and the impact on patients' cognitive function. 【Methods】 A total of 80 patients with DRE admitted to Zhengzhou Central Hospital Affiliated to Zhengzhou University from January 2022 to December 2024 were randomly divided into an observation group and a control group, with 40 patients in each group. Patients in both groups continued to take their original antiepileptic drug regimens. The control group was additionally treated with levetiracetam tablets, while patients in the observation group received lacosamide tablets combined with levetiracetam tablets. Both groups were treated continuously for 6 months. Clinical efficacy, seizure frequency before and after treatment, cognitive function [assessed by the Mini-Mental State Examination (MMSE) score and Montreal Cognitive Assessment (MoCA) score], and serum levels of S-100β protein and neuron-specific enolase (NSE) were compared between the two groups. 【Results】 The total clinical response rate in the observation group (95.00%) was higher than that in the control group (75.00%) (P<0.05). After treatment, seizure frequency and serum levels of S-100β and NSE decreased(all P<0.05), while MMSE and MoCA scores increased in both groups compared with those before treatment (all P<0.05). Moreover, the improvements in the above indicators were more significant in the observation group than in the control group (all P<0.05). 【Conclusion】 Lacosamide tablets combined with levetiracetam tablets can effectively improve clinical efficacy, reduce seizure frequency, improve cognitive function, and decrease serum S-100β and NSE levels in patients with DRE. The therapeutic efficacy of the combined therapy is superior to that of levetiracetam monotherapy.

Key words： Epilepsy Lacosamide Levetiracetam Treatment Outcome

Received: 23 July 2025

PACS:

R742.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SUI Ruibin
	GUO Cancan
	XUE Hongfei
	GAO Lan
	YANG Yahong
	FAN Jinlin
	GUO Dayun

Cite this article:

SUI Ruibin,GUO Cancan,XUE Hongfei, et al. Efficacy of Lacosamide Tablets Combined with Levetiracetam Tablets in the Treatment of Drug-Resistant Focal Epilepsy[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(8): 1253-1255.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.08.006 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I8/1253

[1] 樊修良,白宇彤,杨岸超,等. 难治性癫痫反应性神经电刺激治疗进展[J].中国现代神经疾病杂志,2025,25(1):11-16.
[2] Nascimento F A, Friedman D, Peters J M, et al. Focal epilepsies: update on diagnosis and classification[J]. Epileptic Disord, 2023, 25(1): 1-17.
[3] 谢星星,范玲,黄甫静,等. 左乙拉西坦辅助治疗难治性局灶性癫痫的系统评价[J]. 宁夏医科大学学报,2024,46(8):806-813.
[4] 张超,牛玉明,鄢金柱,等. 抗癫痫发作药物治疗难治性局灶性癫痫的网状Meta分析[J]. 医学新知,2024,34(11):1243-1265.
[5] Chen S M, Fukasawa T, Ikeda A, et al. Adherence to and persistence with lacosamide, perampanel, lamotrigine, and levetiracetam in adult patients with focal epilepsy in Japan: a descriptive cohort study using a claims database[J]. Heliyon, 2023, 9(4): e15017.
[6] 中国抗癫痫协会. 临床诊疗指南:癫痫病分册[M]. 北京: 人民卫生出版社, 2015: 189-190.
[7] Folstein M F, Folstein S E, Mchugh P R. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician[J]. J Psychiatric Res, 1975, 12(3): 189-198.
[8] Carlew A R, Smith E E, Goette W, et al. Montreal Cognitive Assessment (MoCA) scores in medically compromised patients: a scoping review[J]. Health Psychol, 2021, 40(10): 717-726.
[9] Schmitz B, Lattanzi S, Vonck K, et al. Cenobamate in refractory epilepsy: overview of treatment options and practical considerations[J]. Epilepsia Open, 2023, 8(4): 1241-1255.
[10] Mulkerrin G, Hennessy M J. Nonsense mutation in DEPDC5 gene in a patient with carbamazepine-responsive focal epilepsy[J]. Epilepsy Behav Rep, 2024, 27: 100683.
[11] 唐华利,邓君,王菲. 左乙拉西坦联合氯硝西泮对局灶性癫痫患儿的疗效及骨代谢影响[J]. 中国药物应用与监测,2025,22(1):9-12.
[12] 苏杰,段洪波,柴梅,等. 拉考沙胺联合奥卡西平治疗局灶性癫痫的疗效及对脑电图频段功率、血清TLR-4、NF-κB水平影响[J]. 新疆医科大学学报,2024,47(6):867-871.
[13] 程玲玲,张林,张萌. 左乙拉西坦联合丙戊酸钠治疗老年局灶性癫痫临床观察[J]. 中国药业,2024,33(23):103-106.
[14] Zhong G Y, Liang L H, Chen X Z, et al. Therapeutic impact of serum inflammatory cytokines and S-100B levels in patients with acute secondary epilepsy treated with sodium valproate[J]. Am J Ther, 2025, 32(1): e92-e96.
[15] 曹志伟,张润春,王玉珍. 添加拉考沙胺、吡仑帕奈治疗儿童局灶性癫痫的临床疗效及对血清S100β、NSE水平的影响[J]. 中国妇幼健康研究,2024,35(9):49-56.